when should i increase my tirzepatide dose TrimRX Zepbound vs Mounjaro: What's the

The Basics at a Glance Generic name: Retatrutide (development code: LY3437943) Manufacturer: Eli Lilly and Company Drug class: Triple agonist (GLP-1/GIP/glucagon receptor agonist) Administration: Once-weekly subcutaneous injection Dosing range: 2mg to 12mg weekly (gradual titration over 12+ weeks) Half-life: Approximately 6 days (reaches steady state in 45 weeks) FDA status: Phase 3 clinical trials (TRIUMPH program) Expected approval: 20272028 How Retatrutide Differs from Other GLP-1 Medications To understand retatrutide, it helps to see where it fits in the evolution of GLP-1 class medications

For example, decreased sodium excretion (increasing levels) results in water retention and a condition known as volume overload, which causes swelling of tissues (edema)

The mechanisms, dosing, and effects are the same

Pancreatic and gallbladder concerns have been reported with GLP-1 agonists, though causal links remain under investigation